In a nutshell This study evaluated the effectiveness of salvage autologous hematopoietic cell transplantation (ASCT) performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma (MM). The data showed that salvage ASCT performed with stem cells remobilized after previous transplantation is a good treatment...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....
Read MoreEvaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.
In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...
Read MoreEvaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel
In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM). This study concluded that this treatment improves HR-QoL for these patients. Some...
Read MoreEvaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.
In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...
Read MoreHow safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?
In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...
Read MoreEvaluating anti-CD25 radioimmunotherapy with BEAM autologous stem cell transplantation in patients with high-risk relapsed or refractory classical Hodgkin lymphoma
In a nutshell The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin...
Read MoreEvaluating CAR-T cell therapies for treating blood cancers
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...
Read MoreEffects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read MoreEvaluating the effectiveness and safety of ciltacabtagene autoleucel for the treatment of patients with unresponsive multiple myeloma.
In a nutshell This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these...
Read MoreHow useful is a carfilzomib, bendamustine, and dexamethasone treatment combination for hard-to-treat multiple myeloma?
In a nutshell This study reported the safety and effectiveness of a combination of carfilzomib (Kyprolis), bendamustine (Treanda), and dexamethasone (Decadron) for patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a combination of carfilzomib, bendamustine, and dexamethasone (CBd) showed promising...
Read MoreSearching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read More